Onctotarget Leads the Way in Hope for Cancer Patients

When a patient is fighting the battle against cancer, there are many factors that must be taken into consideration to determine the likelihood that they will survive beyond five years. Some of those factors are the current state of the patient’s health at the time of cancer onset, family support systems, normal type of treatment, and the type of cancer. However, just as important, or even more so, is the hope the patient has that there is a chance they will succeed. Oncotarget, a peer-reviewed journal that spans the globe, has shown direct evidence that the more hope a patient has, the more likely they are to live longer than five years with cancer.

Oncotarget focuses many of its articles and research examining the consequences the cancer management programs have on the patient’s mindset. Should these programs increase hope, they review it and recommend it to other oncologists. If these programs decrease hope, they warn other oncologists not to adopt the program. Learn more about Oncotarget at researchgate.net

Recently, Oncotarget was able to recommend the new treatment for papillary thyroid carcinoma that Dr. Carmelo Nucero developed after decades of research. Before this new treatment, papillary thyroid carcinoma posed a problem to oncologists due to its nature to become resistant to vemurafenib. The drug vemurafenib is the most common and affordable drug to treat papillary thyroid carcinoma. When a patient can no longer get vemurafenib, the patient is as good as dead.

The reason that papillary thyroid carcinoma develops a resistance to vemurafenib is that the cancer is based on a mutated BRAF gene. This mutated BRAF gene causes the immune system to attack the drug that is trying to cure it. Follow Oncotarget on Linkedin.

Dr. Carmelo Nucero was able to conduct research in this area and found there is a way to get vemurafenib to bypass the body’s immune system. When vemurafenib is administered at the same time of palbociclib, then the body stops attacking vemurafenib.

Dr. Carmelo Nucero is hopeful that since both drugs are, FDA approved treatment will be greenlighted soon. Catch the full interview on Oncotarget’s podcast now available on iTunes today.

Listen: https://soundcloud.com/oncotarget

Clay Siegall Is Changing The Way That Cancer Is Being Dealt With

Clay Siegall is the co-founder, CEO, President, and Chairman of the Board of Seattle Genetics. He has training as a scientist who has studied targeted cancer therapies and built the company to help people through scientific discovery, diligent research, and developing helpful drugs. The company has made more than $350 million through partnerships with Pfizer, Genentech (Roche), GlaxoSmithKline, and AbbVie and continues to develop antibody-drug-conjugates (ADCs). Its first ADC product was ADCETRIS, which was approved by the FDA in 2011. This ADC has now reached a global audience has been approved for sale in over 65 countries.

Before helping to put together Seattle Genetics, during 1988 to 1991, Clay Siegal worked with the National Cancer Institute and the National Institutes of Health and also Bristol-Myers Squibb Pharmaceutical Research Institute for six years following this. He has 15 patents and has authored over 70 publications and also earned a Bachelor’s of Science in Zoology during his time with the University of Maryland and a Ph.D. from George Washington University in Genetics. He has received many different awards and a couple of these include the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences.

Clay Seigall got into the business of creating ADCs because he has always had an interest in medicine and believes that technology can help the modern world overcome many different kinds of disease. His interest in helping to find treatment for cancer came from a family member who got the disease and then almost died from the conventional form of treatment; chemotherapy. This spurred him to began learning about other kinds of cancer treatment, which he found just as terrible, and it was then that he became motivated to find a better way to help people who suffered with cancer.

Clay Siegall also said that while money has not been the main motivation for his interest in fighting cancer, that it is nice to be able to be your own boss while working to help other people. He believes that it has been through hard work, rather than skill and talent, alone, that he has been able to become the success that he is today.